Home Today's Paper Most Popular Video Gallery Photo Gallery
Subscription Blog Signin Register
Logo
Thursday, November 19, 2020 11:27:01 PM
Follow Us On: Facebook Twitter Twitter Twitter Twitter

Oxford Covid vaccine shows `encouraging` immune response in older adults

By
20th-Nov-2020       
Share
  • Twitter
  • Google+
  • Save
  • E-mail
  • Print
Comments
Share your thought
Post a comment »
Read all () »

News Desk :
The Oxford coronavirus vaccine shows a strong immune response in adults in their 60s and 70s, raising hopes that it can protect age groups most at risk from the virus.
Researchers say the Lancet phase two findings, based on 560 healthy adult volunteers, are "encouraging".
They are also testing whether the vaccine stops people developing Covid-19 in larger, phase three trials.
Early results from this crucial stage are expected in the coming weeks, reports BBC.
Three vaccines - Pfizer-BioNTech, Sputnik and Moderna - have already reported good preliminary data from phase three trials, with one suggesting 94% of over-65s could be protected from Covid-19.
The Oxford data is from an earlier stage, which tests the safety of the vaccine and the body's response to it, but in the long run it's likely this vaccine could be easier to roll out because it doesn't need to be stored at very cold temperatures.
The UK government has ordered more of the Oxford vaccine, manufactured by AstraZeneca, than any other - 100 million doses - compared to 40 million doses of the Pfizer-BioNTech vaccine and five million of the Moderna vaccine.
'Delighted'
Prof Andrew Pollard, study lead from the University of Oxford, told the BBC he was "absolutely delighted with the results" showing a strong immune response "even in those over 70 years of age". On whether the vaccine protects people against Covid-19, he said they were "not there yet" but the data would probably be released "before Christmas".
Prof Pollard said there was "no competition" with other vaccines, adding that multiple vaccines needed to be successful.
"We will need all of them to protect people around the globe," he said.
The challenge with developing a Covid vaccine is to trigger the body to fight back against the virus no matter how old someone is.
Older people's weaker immune systems mean vaccines do not tend to function as well as they do in younger people. These trial results from the University of Oxford, peer-reviewed in the Lancet, suggest that may not be a problem.
They show that older adults aged 56-69 and over 70 had a similar immune response to younger adults aged 18-55.
'Protect most vulnerable'
Dr Maheshi Ramasamy, an investigator at the Oxford Vaccine Group, said: "The next step will be to see if this translates into protection from the disease itself."
Two weeks after the second dose, more than 99% of participants had neutralising antibody responses. These included people of all ages.
The T-cell response - another measure of how well the immune system responds - peaked two weeks after the first dose of the vaccine, regardless of age.
"The robust antibody and T-cell responses seen in older people in our study are encouraging," Dr Ramasamy said.
"The populations at greatest risk of serious Covid-19 disease include people with existing health conditions and older adults. "We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure."
Older adults were also less likely to experience side-effects, which were usually mild.
And there were no serious safety issues relating to the vaccine, called ChAdOx1 nCov-2019.
Volunteers in the trial were put into groups and given one or two doses of the vaccine or a dummy jab. The reaction of their immune systems was assessed on the day they got the jab, then one, two and four weeks after both doses.
The Oxford vaccine is made from a weakened version of a common cold virus (known as an adenovirus) from chimpanzees that has been modified so it cannot grow in humans.
Work began on the vaccine in January and it was developed in under three months, starting human trials - the first in Europe - in April in Oxford.
Phase three trials of the vaccine, which look at how effective it is at protecting people against the Covid-19, started at the end of August and are still continuing.
When data from this stage is sent to the regulators, scrutinised and approved, the vaccine can be given the green light to be used on people worldwide.
The Oxford vaccine is expected to be easier to manufacture on a global scale than Pfizer and Moderna's vaccine, and the university is committed to making hundreds of millions of doses available to the developing world.

Tariff
Simtex-Group></a></div> <div id=Add Rate

News Archive

Inside The New Nation

Editorial »

People are helpless when public offices remain indifferent to public health


THE government's zero-tolerance policy 'no mask, no entry' for public offices does not affect and explicitly ignored, posing the risk of spreading contagion in the upcoming winter, when the second-wave of the Coronavirus is feared. People are reluctant to wear masks while the authorities turn a blind eye to this ...

Sports »

Nadal vows to keep fighting after Thiem loss at ATP Finals


Rafael Nadal insisted he can still win the ATP Finals for the first time despite a damaging 7-6 (9/7), 7-6 (7/4) defeat against Austria's Dominic Thiem on Tuesday.Thiem overpowered Nadal behind closed doors at London's O2 Arena to put a dent in the Spanish star's bid to finally lift the ...

Sports »

FIFA cancels next year's Women's U-17 World Cup in India


The Women's Under-17 World Cup in India, which was postponed to 2021 due to Covid-19 pandemic, was on Tuesday cancelled by the world governing body FIFA and the country was handed the hosting rights of the 2022 edition.The decision was taken by the Bureau of the FIFA Council which took ...

City »

Chief of Air Staff Air Chief Marshal Masihuzzaman Serniabat cuts cake at the BAF Colours Award Ceremony of different units and squadrons of BAF at the parade ground of BAF Base Bashar on Wednesday.


Business & Economy »

Mirza Elias Uddin Ahmed, Managing Director of Jamuna Bank Limited and Jashim Uddin, Managing Director of Jamuna Life Insurance Company Limited, jointly handing over a claim cheque to a nominee of a Credit Card coverage scheme user who died from normal diseases recently. Adnan Mahmud Ashrafuzzaman, Head of Cards and ABM Saadi, Head of ADC of the bank were also present.


.

International »

Obama`s description of Indian leaders in memoir causes flutter


Al Jazeera News :Former US President Barack Obama's descriptions of India's leaders in his new memoir, A Promised Land, has caused ripples in political circles, with former Indian Prime Minister Manmohan Singh receiving praise.The book, released on Tuesday, covers his campaign for the White House and his first term in ...

Editorial »

Nobody is ready to listen to experts for improving city`s traffic system


CITY traffic system is in total disarray said a report in a national daily mainly blaming indiscipline parking and haphazard pedestrians' road crossing as well as poor signalling system. It is causing gridlock in city streets at major intersections trailing long queue behind. The report based on findings of 'Accident ...

International »

No room for complacency with Covid-19 cases surging : WHO Chief


UN news :Voicing deep concern over the surge of Covid-19 cases, WHO Chief Tedros Adhanom Ghebreyesus has warned about the risk of complacency with the encouraging news about vaccines.He said the UN agency is "extremely concerned" by the surge in cases in some countries which is pushing health workers and ...

Football »

An honour to have Ronaldo break my record, says Iran's Daei


Former Iran striker Ali Daei has said he would be honored to see Cristiano Ronaldo break his record for the most goals in international soccer as the Portugal forward moves closer to his tally of 109.Ronaldo, the only other centurion in the men's international arena, has scored 102 goals in ...

Sports »

Medvedev wins with underarm serve at ATP Finals


Daniil Medvedev pulled off an underarm serve as he outlasted Alexander Zverev and joined Novak Djokovic as a winner at the ATP Finals on day two Monday.Medvedev prevailed 6-3, 6-4, while Djokovic cruised past Finals debutant Diego Schwartzman 6-3, 6-2 in an empty O2 Arena.Djokovic and Medvedev meet on Wednesday ...

City »

Controller General Defence Finance (Additional Charge) Dr. Shyamal Kanti Chowdhury inaugurates 'Bangabandhu Corner' at the Head Office of CGDF in the city on Monday marking birth centenary of Father of the Nation Bangabandhu Sheikh Mujibur Rahman.


Entertainment »

Salma returns to stage show


Entertainment Report :At last, after a break of eight months, popular singer of present time Salma Akter is returning to stage show. She will return to a stage show at Krishibid Institution in the capital on November 20. Salma is very much excited to perform in this show. While talking ...

Editorial »

Banking services vulnerable to theft-robbery


It is mystifying that nobody knows what is going to be happened in Sonali Bank's Uthali branch in Jiban Nagar upazila of Chuadanga district on Sunday afternoon. The daring act of a group of three armed robbers in broad daylight has left locals and employees of the bank branch, which ...

Business & Economy »

Rebecca Brosnan made Director of City Bank by IFC


Business Desk :Rebecca Brosnan has been appointed in the City Bank Board as nominated Director of IFC (International Finance Corporation). IFC, a member of World Bank Group, is holding 5 per cent share of the bank since 2017, said a press release.Brosnan is now the Chief Operating Officer of Mother's ...

Business & Economy »

FSL gets new MD


Business Desk :Selim Chowdhury joined as the Managing Director of First Solutions Limited. Prior, served as Managing Director of G4S Bangladesh for 20 years. The company has started its journey in the services industry from 01 November 2020. Having vision to provide a wide range of services in private security, ...

 
Items that you save may be read at any time on your computer, iPad, iPhone or Android devices.
 
Are you new to our website? Do you have already an account at our website?
Create An Account Log in here
Email this news to a friend or like someone
Email:
Write a comment to this news